Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Sulfur – selenium or tellurium compound
Reexamination Certificate
2008-01-22
2008-01-22
Witherspoon, Sikarl A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Sulfur, selenium or tellurium compound
C514S708000, C568S022000
Reexamination Certificate
active
07321002
ABSTRACT:
The invention provides enantiomers of ajoene and derivatives of Z(−)-ajoene. The derivative of Z(−)-ajoene are useful for modulating integrin-mediated functions, for treating disorders, diseases or conditions in which integrins play a role, and for treating tissues to improve their condition for a subsequent use, such as transplantation.
REFERENCES:
patent: 4126676 (1978-11-01), Sanders
patent: 4239778 (1980-12-01), Venton et al.
patent: 4274410 (1981-06-01), Chvapil
patent: 4341762 (1982-07-01), Haast
patent: 4643994 (1987-02-01), Block et al.
patent: 4665088 (1987-05-01), Apitz-Castro et al.
patent: 4876281 (1989-10-01), Yoshida et al.
patent: 5066658 (1991-11-01), Demers et al.
patent: 5093122 (1992-03-01), Kodera
patent: 5279941 (1994-01-01), Lessey
patent: 5380646 (1995-01-01), Knight et al.
patent: 5464855 (1995-11-01), Capiris et al.
patent: 5478725 (1995-12-01), Lessey
patent: 5731288 (1998-03-01), Markland, Jr. et al.
patent: 5856363 (1999-01-01), Tatarintsev et al.
patent: 5863954 (1999-01-01), Tatarintsev et al.
patent: 5863955 (1999-01-01), Tatarintsev et al.
patent: 5932621 (1999-08-01), Tatarintsev
patent: 5948821 (1999-09-01), Tatarintsev et al.
patent: 5968988 (1999-10-01), Tatarintsev
patent: 5981602 (1999-11-01), Tatarintsev et al.
patent: 6177475 (2001-01-01), Tatarintsev et al.
patent: 7045663 (2006-05-01), Davidson et al.
patent: 153881 (1985-09-01), None
patent: 185324 (1986-06-01), None
patent: WO 94/15953 (1994-07-01), None
Int'l Search Report for PCT/US01/21826, Oct. 30, 2001, Davidson, John B.
Perbec, L.; Hedqvist, P. “Prostaglandins E1And E2Antagonize Indomethacin-Induced Decrease in Survival Rate Of Haemorrhagically Shocked Rats,”Act Chir Scand., suppl. 1980, 500, 91-94.
Bourinbaiar, A. S.; Nagorny, R. “Human Immunodeficiency Virus Type 1 Infection of Choriocarcinoma-Derived Trophoblasts,”Acta. Virol.,1993, 37, 21-28.
Liu, D. Y.; Kaymakcalan, Z. “In Vitro Adhesion Assay,” Adhesion: Its Role in Inflammatory Disease, (Harlan, J. M.; Liu, D. Y. eds., W.H. Freeman and Company 1992),Appendix, 189-193.
Harlan, J. M.; Winn, R. K.; Vedder, N. B.; Doerschuk, C. M.; Rice, C. L. “In Vivo Models Of Leukocyte Adherence To Endothelium,” Adhesion: Its Role in Inflammatory Disease, (Harlan, J. M.; Liu, D. Y. eds., W.H. Freeman and Company 1992),Chapter 6, 117-150.
Liu, D. Y.; Harlan, J. M. “Outlook For The Future,” Adhesion: Its Role in Inflammatory Disease, (Harlan, J. M.; Liu, D. Y. eds., W.H. Freeman and Company 1992),Chapter 8, 183-187.
Levy, J. A. “Viral and Cellular Factors Influencing HIV Tropism,” Mechanisms and Specificity of HIV Entry Into Host Cells, (Düzgünes, N. ed., Plenum Press 1991), 1-15.
Meyers, K. M. “Pathobiology of Animal Platelets,”Adv. Vet. Sci. Comp. Med.,1985, 30, 131-165.
Phillips D. M. “The Role of Cell-to-Cell Transmission in HIV Infection,”AIDS, 1994, 8, 719-731.
Johnson, V. A. “New Developments In Antiretroviral Drug Therapy for HIV Infection,”AIDS Clinical Review, 1992, 70-104.
Stevenson, M.; Bukrinsky, M.; Haggerty, S. “HIV-1 Replication and Potential Targets for Intervention,”AIDS Res. and Human Retrovir., 1992, 8, 107-117.
Butera, S. T.; Folks, T. M. “Application of Latent HIV-1 Infected Cellular Models to Therapeutic Intervention,”AIDS Res. and Human Retrovir., 1992, 8, 991-995.
Kolson, D. L.; Buchhalter, J.; Collman, R.; Hellmig, B.; Farrell, C. F.; Debouck, C.; Gonzalez-Scarano, F. “HIV-1 Tat Alters Normal Organization of Neurons and Astrocytes in Primary Rodent Brain Cell Cultures: RGD Sequence Dependence,”AIDS Res. and Human Retrovir., 1993, 9, 677-685.
Guo, M. M. L.; Hildreth J. E. K. “HIV Acquires Functional Adhesion Receptors from Host Cells,”Aids Research And Human Retroviruses, 1995, 11, 1007-1013.
Hsueh, W.; Gonzalez-Crussi, F.; Arroyave, J. L. “Platelet-Activating Factor-Induced Ischemic Bowel Necrosis,”AJP, 1986, 122, 231-239.
Acosta, E. P.; Fletcher, C. V. “Agents for Treating Human Immunodeficiency Virus Infection,”Am. J. Hosp. Pharm., 1994, 51, 2251-2267.
Zutter, M. M.; Mazoujian, G.; Santoro, S. A. “Decreased Expression Of Integrin Adhesive Protein Receptors in Adenocarcinoma Of The Breast,”American Journal Of Pathology, 1990, 137, 863-870.
Feuerstein, G.; Hallenbeck, J. M. “Prostaglandins, Leukotrienes, and Platelet-Activating Factor in Shock,”Am. Rev. Pharmacol. Toxicol., 1987, 27, 301-313.
Bone, Roger C. “The Pathogenesis of Sepsis,”Annals of Internal Medicine, 1991, 115, 457-469.
Henderson, W. R. “The Role of Leukotrienes in Inflammation,”Ann. Intern. Med., 1994, 121, 684-697.
Mueller, B. M.; Reisfeld, R. A.; Silveira, M. H.; Duncan, J. D.; Wrasidlo, W. A. “Pre-Clinical Therapy of Human Melanoma with Morpholino-Doxorubicin Conjugated to a Monoclonal Antibody Directed Against an Integrin on Melanoma Cells,”Antibody, Immunoconjugates, and Radiopharmaceuticals, 1991, 4, 99-106.
Tadi, P. P.; Lau, B. H. S.; Teel, R. W.; Herrmann, C. F. “Binding of Aflatoxin B1to DNA by Ajoene and Diallyl Sulfide,”Anticancer Research, 1991, 11, 2037-2042.
Chambers, A. F.; Behrend, E. I.; Wilson, S. M.; Denhardt, D. T. “Induction of Expression of Osteopontin (OPN; Secreted Phosphoprotein) in Metastatic,Ras-Transformed, NIH 3T3 Cells,”Anticancer Research, 1992, 12, 43-48.
Delaha, E. C.; Garagusi, V. F. “Inhibition of Mycobacteria by Garlic Extract (Allum sativum),”Antimicrob. Agents Chemother., 1985, 27, 485-486.
San-Blas, G.; San-Blas, F.; Gil, F.; Marino, L.; Apitz-Castro, R. “Inhibition of Growth of the Dimorphic FungusParacoccidioides brasiliensisby Ajoene,”Antimicrobial Agents and Chemotherapy, 1989, 33, 1641-44.
Perez, H. A.; De La Rosa, M.; Apitz, R. “In Vivo Activity of Ajoene against Rodent Malaria,”Antimicrobial Agents and Chemotherapy, 1994, 38, 337-339.
Bridges, C. G.; Brennan, T. M.; Taylor, D. L.; McPherson, M.; Tyms, A. S. “The Prevention of Cell Adhesion and the Cell-to-Cell spread of HIV-1 In Vitro by the α-glucosidase 1 Inhibitor, 6-O-butanoyl Castanospermine (MDL 28574),”Antiviral Research, 1994, 25, 169-175.
Yoshida, S.; Kasuga, S.; Hayashi, N.; Ushiroguchi, T.; Matsuura, H.; Nakagawa, S. “Antifungal Activity of Ajoene Derived from Garlic,”Applied and Environmental Microbiology, 1987, 53, 615-17.
Nock, L.P.; Mazelis, M. “C-S Lyases of Higher Plants: Preparation and Properties of Homogeneous Alliin Lyase from Garlic (Allium sativum),”Archives of Biochemistry and Biophysics, 1986, 249, 27-33.
Hite, L. A.; Jia, L-G.; Bjarnason, J. B.; Fox, J. W. “cDNA Sequences for Four Snake Venom Metalloproteinases: Structure, Classification, and Their Relationship to Mammalian Reproductive Proteins,”Archives of Biochemistry and Biophysics, 1994, 308, 182-191.
Kavanaugh, A. F.; Davis, L. S.; Nichols, L. A.; Norris, S. H.; Rothlein, R. Scharschmidt, L. A.; Lipsky P. E. “Treatment of Refractory Rheumatoid Arthritis With a Monoclonal Antibody to Intercellular Adhesion Molecule 1,”Arthritis&Rheumatism, 1994, 37, 992-999.
Oelkers, B.; Diehl, H.; Liebig, H. “In Vitro Inhibition of Cytochrome P-450 Reductases from Pig Liver Microsomes by Garlic Extracts,”Arzneim.-Forsch/Drug Res., 1992, 42, 136-39.
Bordia, A. “Effect of Garlic on Human Platelet Aggregation In Vitro,”Atherosclerosis, 1978, 30, 355-60.
Bachelot, C.; Cano, E.; Grelac, F.; Saleun, S.; Druker, B. J.; Levy-Toledano, S.; Fischer, S.; Rendu, F. “Functional Implications of Tyrosine Protein Phosphorylation in Platelets,”Biochem J., 1992, 284, 923-28.
Huang, T-F.; Sheu, J-R.; Teng, C-M. “A Potent Antiplatelet Peptide, Triflavin, From Trimeresurus Flavoviridis Snake Venom,”Biochem J., 1991, 277, 351-357.
Zhuang, Q.; Stracher, A. “Purification and Characterization of a Calcium
Davidson John B.
Hildreth James K.
Tatarintsev Alexander V.
Turgiev Ali S.
Billings Pharmaceuticals, Inc.
Brinks Hofer Gilson & Lione
Witherspoon Sikarl A.
Zayia Gregory H.
LandOfFree
Chiral integrin modulators and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chiral integrin modulators and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chiral integrin modulators and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2791851